Search

Your search keyword '"P L, Meroni"' showing total 4 results
Start Over Author "P L, Meroni" Topic rheumatology
4 results on '"P L, Meroni"'

1. POS0721 ASSOCIATION BETWEEN PRECONCEPTION COMPLEMENT LEVELS AND USE OF HYDROXYCHLOROQUINE WITH PREGNANCY OUTCOME IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME AND CARRIERS OF ANTIPHOSPHOLIPID ANTIBODIES: AN INTERNATIONAL MULTICENTER STUDY

Author

D. Lini, C. Nalli, L. Andreoli, F. Crisafulli, M. Fredi, M. G. Lazzaroni, V. Bitsadze, A. Calligaro, V. Canti, R. Caporali, F. Carubbi, C. Chighizola, P. Conigliaro, F. Conti, C. De Carolis, T. Del Ross, M. Favaro, M. Gerosa, A. Iuliano, J. Khizroeva, A. Makatsariya, P. L. Meroni, M. Mosca, M. Padovan, R. Perricone, P. Rovere-Querini, G. D. Sebastiani, C. Tani, M. Tonello, S. Truglia, D. Zucchi, F. Franceschini, and A. Tincani

Subjects
Rheumatology, Immunology, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology
Abstract

BackgroundAntiphospholipid Syndrome (APS) is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for antiphospholipid antibodies (aPL). Complement was demonstrated to be involved in aPL-related pregnancy loss in animal models and several groups investigated the significance of complement levels in human disease. C3 and C4 serum levels were assessed in several cohorts of pregnant patients with APS and/or aPL positivity in order to relate complement consumption with adverse pregnancy outcome (APO).According to some authors, hydroxychloroquine (HCQ) can control the activation of the complement system, improve pregnancy outcome and reduce aPL title.ObjectivesThis study was designed to verify the effect of HCQ in addition to low dose aspirin (LDA) + low molecular weight heparin (LMWH) treatment in a multicenter cohort of primary APS (PAPS) and aPL carriers pregnant women and the possible correlation with preconception serum C3/C4 levels.MethodsMedical records of pregnant women with confirmed positivity for aPL antibodies attending twelve referral centers from January 2010 to December 2020 were retrospectively evaluated. We considered as aPL-related APO: spontaneous abortions (ResultsWe have analyzed 164 singleton PAPS/aPL carrier pregnancies (22 aPL carriers - 13%) in 128 patients: all were treated with combination therapy (LDA+LMWH), and in 30 HCQ was added. 58 pregnancies (43%) had low levels of preconception C3/C4. A triple aPL positivity was observed in 54 pregnancies, 14 of them were treated with combination therapy + HCQ. When considering the whole cohort, the addition of HCQ had not significantly improved the gestational outcome. Further stratification was performed on the basis of complement consumption. In the group of patients with preconception low C3/C4 levels the addition of HCQ had not significantly improved pregnancy outcome. We have lastly evaluated 40 pregnancies with a high-risk profile (triple aPL positivity and complement consumption), in which we have found that HCQ significantly improved gestational outcome (p=0.018, Table 1).Table 1.Relationship between APO, therapy during pregnancy and risk profile.All pregnancies (n=164)Reduced C3/C4 (n=58)Triple aPL+ and reduced C3/C4 (n=40)LDA+LMWH (n, %)LDA+LMWH+HCQ (n, %)pLDA+LMWH (n, %)LDA+LMWH+HCQpLDA+LMWHLDA+LMWH+HCQp(n, %)(n, %)(n, %)APO62 (46%)16 (53%)ns32 (68%)4 (36%)ns23 (77%)3 (30%)0.018No APO72 (54%)14 (47%)15 (32%)7 (64%)7 (23%)7 (70%)Total1343047113010This observation could not be confirmed in patients with single or double aPL positivity.ConclusionThe study shows that administering HCQ in addition to combination therapy can improve gestational outcome in aPL/PAPS high-risk patients. This observation confirms that HCQ exerts a beneficial effect on aPL pregnancies by complement inhibition as it was shown in animal models. In addition, our results provide the clinicians a useful tool to implement conventional treatment in patients at high risk of pregnancy complication or loss.References[1]De Carolis S, et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? Autoimmun Rev 2015;14:760-2.[2]Mekinian A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in antiphospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015;40:498-502.[3]Mekinian A et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev 2015;14:23-9.Disclosure of InterestsNone declared

Published
2022
Full Text
View/download PDF

2. Autoantibody profiling in APS

Author

D, Roggenbuck, V, Somma, P, Schierack, M O, Borghi, and P L, Meroni

Subjects
Pathology, medicine.medical_specialty, Reduced risk, biology, business.industry, Autoantibody, Enzyme-Linked Immunosorbent Assay, Antiphospholipid Syndrome, medicine.disease, Rheumatology, beta 2-Glycoprotein I, immune system diseases, Antiphospholipid syndrome, Antibodies, Anticardiolipin, Immunology, Antibodies, Antiphospholipid, biology.protein, medicine, Humans, Line immunoassay, Antibody, Clinical phenotype, business, neoplasms, Autoantibodies
Abstract

The international consensus for the classification of antiphospholipid syndrome (APS) requires clinical and laboratory criteria to be considered at an equal level for diagnosing APS. Thus, detection of antiphospholipid antibodies (aPL) being a hallmark of APS has been the object of intensive investigation over the past 40 years. However, appropriate detection of aPL still remains a laboratory challenge due to their heterogeneity comprising autoantibodies reactive to different phospholipid-binding plasma proteins, such as beta-2 glycoprotein I (β2GPI) and prothrombin. The relevance of aPL interacting with phospholipids other than cardiolipin (CL, diphosphatidylglycerol), such as phosphatidylserine (PS), remains elusive with regard to the diagnosis of APS. Recently, the concept of aPL profiling has been introduced to assess the risk of thrombotic complications in patients with APS. New assay techniques, apart from enzyme-linked immunosorbent assays (ELISAs) recommended by the international consensus for the classification of APS, have been proposed for multiplexing of aPL testing. Line immunoassays (LIAs) employing a novel hydrophobic solid phase for the simultaneous detection of different aPL seem to be an intriguing alternative. We evaluated a novel multiplex LIA employing a hydrophobic membrane coated with different phospholipid (PL)-binding proteins or PLs. The performance characteristics of this new multiplexing assay technique demonstrated its usefulness for aPL profiling.

Published
2014
Full Text
View/download PDF

3. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period:a multicentre prospective study of 1000 patients

Author

R, Cervera, R, Serrano, G J, Pons-Estel, L, Ceberio-Hualde, Y, Shoenfeld, E, de Ramón, V, Buonaiuto, S, Jacobsen, M M, Zeher, T, Tarr, A, Tincani, M, Taglietti, G, Theodossiades, E, Nomikou, M, Galeazzi, F, Bellisai, P L, Meroni, R H W M, Derksen, P G D, de Groot, M, Baleva, M, Mosca, S, Bombardieri, F, Houssiau, J-C, Gris, I, Quéré, E, Hachulla, C, Vasconcelos, A, Fernández-Nebro, M, Haro, Z, Amoura, M, Miyara, M, Tektonidou, G, Espinosa, M L, Bertolaccini, M A, Khamashta, Manuel, Abarca, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre National de Référence du Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Maladies Auto-immunes Systémiques Rares [CHU Pitié Salpêtrière], Service de Médecine Interne 2, maladies auto-immunes et systémiques [CHU Pitié-Salpêtrière], Institut E3M [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut E3M [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Universitat de Barcelona

Subjects
Male, Pediatrics, Autoimmune diseases, Transient ischaemic attacks, Biochemistry, Cohort Studies, Pregnancy, Antiphospholipid syndrome, Immunology and Allergy, Lupus Erythematosus, Systemic, Longitudinal Studies, Prospective Studies, Prospective cohort study, Child, Stroke, ComputingMilieux_MISCELLANEOUS, Medicine(all), Anticardiolipin Antibodies, Aged, 80 and over, Venous Thrombosis, Fetal Growth Retardation, Malalties autoimmunitàries, Pregnancy Outcome, Síndrome antifosfolipídica, Orvostudományok, Middle Aged, Antiphospholipid Syndrome, 3. Good health, Pulmonary embolism, Multicenter Study, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Estudi de casos, Ischemic Attack, Transient, Child, Preschool, Cohort, Premature Birth, Female, Cohort study, Adult, medicine.medical_specialty, Adolescent, Immunology, Observational Study, Infections, Klinikai orvostudományok, Systemic Lupus Erythematosus, General Biochemistry, Genetics and Molecular Biology, Autoimmune Diseases, Young Adult, Rheumatology, medicine, Journal Article, Antiphospholipid Antibodies, Humans, Aged, Livedo Reticularis, Lupus erythematosus, Epilepsy, business.industry, Biochemistry, Genetics and Molecular Biology(all), Infant, Newborn, Infant, Thrombosis, medicine.disease, Thrombocytopenia, Surgery, Abortion, Spontaneous, Morbiditat, Lupus eritematós, Case studies, Morbidity, business, Pulmonary Embolism, Genetics and Molecular Biology(all)
Abstract

ObjectivesTo assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later.MethodsIn 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years.Results53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%.ConclusionsPatients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.

Published
2015
Full Text
View/download PDF

4. IX Eular Workshop for Rheumatology Research

Author

C. Fournier, B. Texier, G. Chiocchia, M. C. Boissier, D. Herbage, C. M. S. Brown, C. Plater Zyberk, R. N. Maini, A. Palacios, J. Sieper, D. Heinegard, G. S. Panayi, A. Gentric, L. Mackenzie, P. M. Lydyard, P. Youinou, E. J. Menzel, B. Kaik, Yu. K. Sykulev, A. Je. Guschin, V. I. Vasiljev, K. K. Ostreiko, T. V. Yeronina, I. A. Tumanova, M. Moynier, M. Abderrazik, B. Combe, M. Rucheton, J. Brochier, T. Tuomi, T. Palosuo, M. Heliövaara, K. Aho, N. J. McHugh, I. E. James, C. G. M. Kallenberg, J. W. Cohen Tervaert, R. Goldschmeding, A. E. G. K. R. Von Dem Borne, M. Bouanani, M. Piechaczyk, B. Pau, M. Bastide, S. Le Page, W. Williams, D. Parkhouse, G. Cambridge, D. A. Isenberg, J. Nimmegeers, F. De Keyser, G. Verbruggen, E. M. Veys, M. J. F. Walravens, I. Verdeyen, B. Vandepol, W. Cortens, L. Schatteman, K. Goethals, D. -H. Wu, A. Tavoni, R. Neri, C. Garzelli, C. Vitali, S. Bombardieri, D. Logar, T. Kveder, J. Dobovisek, B. Rozman, H. A. Menard, G. Boire, F. J. Lopez-Longo, Ch. Masson, S. Lapointe, E. W. St. Clair, L. Zerva, H. M. Moutsopoulos, J. D. Keene, D. S. Pisetsky, A. P. Van Dam, H. T. M. Cuypers, I. Winkel, R. J. T. Smeenk, D. Taylor, E. Valente, J. P. Foster, D. G. Williams, M. R. Stocks, R. Caporali, F. De Gennaro, A. Cerino, F. Cobianchi, G. C. B. Astaldi-Ricotti, C. Montecucco, W. Habets, P. T. G. Sillekens, M. H. Hoet, G. McAllister, M. R. Lerner, W. J. Van Venrooij, W. J. Habets, A. Van Der Kemp, B. De Jong, R. Scarpa, A. Pucino, C. Di Girolamo, G. della Valle, G. Larizza, D. Casiere, P. Oriente, L. Paimela, J. Palvimo, P. Kurki, W. Hassfeld, G. Steiner, W. Graninger, J. S. Smolen, E. J. Lopez-Longo, A. Larose, R. Hoet, R. Zewald, R. Smeenk, K. Brinkman, H. Van Den Brink, A. Westgeest, R. Huss, E. F. Krapf, M. Herrmann, W. Leitmann, J. R. Kalden, K. Merétey, L. Cebecauer, U. Böhm, D. Kozakova, M. Brózik, P. Temesvári, L. Nagy, B. Bozic, M. Stegnar, N. Vene, P. Peternel, C. Giuggioli, P. Monti, G. Rossi, C. Ferri, S. Chiellini, C. Baboonian, P. J. W. Venables, L. Roffe, J. Booth, F. Krapf, I. Abuljadayel, A. Ebringer, N. L. Cox, S. R. Brand, D. P. McIntosh, R. M. Bernstein, M. F. Van Den Broek, M. C. J. Van Bruggen, T. Smetsers, P. Kuyer, L. Van De Putte, W. B. Van Den Berg, A. Toivanen, S. Jalkanen, R. Lahesmaa-Rantala, O. Isomäki, K. Pekkola-Heino, R. Merilahti-Palo Saario, R. Von Essen, H. Isomäki, K. Granfors, J. S. H. Gaston, P. F. Life, L. Bailey, P. A. Bacon, S. Khalafpour, C. Wilson, J. Awad, P. Toivanen, R. Saario, M. Skurnik, C. Van Der Straeten, H. Mielants, M. Gazic, K. Hartung, T. Riedel, S. Stannat, Ch. Specker, E. Röther, K. Pirner, D. Schendel, M. Baur, A. Corvetta, H. H. Peter, H. J. Lakomek, H. Deicher, A. P. Andonopoulos, C. A. Papasteriades, A. A. Drosos, G. S. Dimou, W. Shattles, P. Venables, P. J. Charles, J. R. Markwick, P. J. Venables, M. Galeazzi, P. Lulli, T. Tuzi, S. Cappellacci, M. Morellini, S. Trabace, F. Cutrupi, R. Sorrentino, S. Botti, C. Iannicola, S. Costanzi, R. Tosi, A. Gospodinoff, J. F. Eliaou, H. Humbert, P. Balaguer, J. C. Nicolas, J. Sany, J. Clot, L. I. Sakkas, H. Bird, K. I. Welsh, C. Pitzalis, G. Kingsley, D. Haskard, T. L. Vischer, S. Bas, C. Werner-Favre, D. Wohlwend, R. H. Zubler, A. Afeltra, O. De Pita, P. Basso, A. Pietrucci, G. M. Ferri, L. Bonomo, R. Gerli, C. Cernetti, A. Bertotto, E. Agea, C. Arcangeli, L. Lanfrancone, P. Rambotti, S. Crupi, A. Baglioni, F. Spinozzi, S. Papazoglou, D. Skoumi, P. Athanasiou, A. Iliopoulos, A. Stavropoulou, T. Kontomerkos, G. Hendrich, J. G. Kuipers, M. Hammer, R. E. Schmidt, M. N. Manoussakis, G. Germandis, L. V. Zerva, H. J. Siouna-Fatourou, P. D. Katsikis, A. Mavridis, A. Toubert, M. Sadouk, B. de la Tour, C. Vaquero, B. Amor, P. Miossec, M. Naviliat, I. Cretien, J. Banchereau, P. Graninger, B. Aschauer, A. Sinski, J. Smolen, J. Krutmann, R. Kirnbauer, A. Köck, T. Schwarz, L. T. May, P. B. Sehgal, T. A. Luger, M. Field, C. Q. Chu, M. Feldmann, B. Wilbrink, J. J. Nietfeld, M. Helle, L. C. M. Boeije, J. L. A. M. Van Roy, W. Den Otter, L. A. Aarden, O. Huber-Bruning, J. Malejczyk, A. Urbanski, M. Malejczyk, A. Karbowski, W. Völker, U. Feige, A. M. Malfait, N. Wieme, L. Gyselbrecht, A. A. J. Van de Loo, P. L. E. M. Van Lent, D. O. Haskard, S. Wellicome, J. Lanchbury, M. Thornhill, K. Krutmann, F. Gschnait, M. Yaron, I. Yaron, J. -M. Dayer, I. Bleiberg, F. -A. Meyer, C. P. J. Maury, A. -M. Teppo, E. Salo, P. Pelkonen, A. Malfait, Ph. Cochez, M. Gruschwitz, P. U. Müller, G. Wick, R. Madhok, R. Wilson, M. Frame, J. Thompson, R. D. Sturrock, G. Partsch, M. Matucci-Cerinic, S. Marabini, S. Jantsch, J. Neumüller, R. Eberl, H. M. van Beuningen, O. J. Arntz, G. J. Zlabinger, C. Steffen, H. S. Brand, G. P. J. Van Kampen, M. H. M. T. De Koning, E. Kiljan, J. K. Van Der Korst, C. G. Gemmell, A. J. G. Swaak, A. Van Rooyen, N. D. Hall, A. D. Woolf, B. Kantharia, J. Maymo, D. R. Blake, N. J. Goulding, P. J. Maddison, E. Munthe, H. B. Berntzen, M. Fagerhol, A. Mathieu, R. Pala, L. Contu, R. Cirillo, P. Garau, P. Nurchis, G. C. Viberti, O. Meyer, C. Zenklusen, Z. Le Thi Huong Du, C. Gaudouen, J. Ph. Mery, P. Ronco, M. F. Kahn, N. Rasmussen, W. Szpirt, B. Thomsen, R. L. Humbel, E. J. Ter Borg, G. Horst, E. Hummel, P. C. Limburg, A. Aeschilmann, P. Bourgeois, D. J. De Rooij, L. B. A. Van de Putte, L. Verbeek, C. Farinaro, E. Infranzi, M. Couret, C. Ackerman, K. De Vlam, V. Carapic, D. Carapic, M. Annefeld, B. Erne, L. J. Rosenwasser, C. J. Pazoles, I. G. Otterness, D. C. Hanson, B. McDonald, L. D. Loose, M. Dougados, K. P. Machold, I. Wiesenberg-Böttcher, K. Wanner, W. Pignat, H. Altmann, H. Tuschl, H. Bröll, G. Balestrieri, A. Tincani, R. Cattaneo, M. T. Bertoli, M. Martinelli, F. Allegro, P. L. Meroni, G. Balesini, G. Aichinger, E. Schlögl, Ch. Huber, Y. Shoenfeld, E. Fleishmaker, S. Mendlovic, E. Mozes, M. Blank, N. Talal, E. J. M. Hogervorst, W. Van Eden, R. Van Der Zee, D. Psychos, G. Dimou, S. Stefanaki-Nikou, C. S. Papadimitriou, L. Settas, P. Alexiou, G. Dimitriadis, E. Mataftsi, E. Soliou, A. Tourkantonis, M. Babic, M. E. C. Jeurissen, and A. MTh Boerbooms

Subjects
030203 arthritis & rheumatology, medicine.medical_specialty, business.industry, Public health, General Medicine, Rheumatology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Family medicine, medicine, 030212 general & internal medicine, business
Published
1989
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results